IL33 and diabetes mellitus: The above-mentioned studies and those showing the involvement of other pro-inflammatory molecules like IL-1β, IL-6, IL-13, IL-33 and their receptors [55,56] constitute a proof of concept that chronic inflammation is implicated in the pathophysiology of diabetes; therefore, targeting inflammation may ameliorate diabetes and insulin resistance, preventing its progression and any vascular complications.